Found: 21
Select item for more details and to access through your institution.
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
- Published in:
- Frontiers in Neurology, 2019, p. N.PAG, doi. 10.3389/fneur.2019.00253
- By:
- Publication type:
- Article
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2020, p. 1, doi. 10.1177/2055217320972137
- By:
- Publication type:
- Article
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2020, v. 6, n. 4, p. 1, doi. 10.1177/2055217320972137
- By:
- Publication type:
- Article
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 842, doi. 10.1177/13524585211061335
- By:
- Publication type:
- Article
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 14, p. 1866, doi. 10.1177/1352458519888610
- By:
- Publication type:
- Article
Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 13, p. 1719, doi. 10.1177/1352458519881759
- By:
- Publication type:
- Article
Iron Is a Sensitive Biomarker for Inflammation in Multiple Sclerosis Lesions.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0057573
- By:
- Publication type:
- Article
Concise Review: Modeling Multiple Sclerosis With Stem Cell Biological Platforms: Toward Functional Validation of Cellular and Molecular Phenotypes in Inflammation-Induced Neurodegeneration.
- Published in:
- Stem Cells Translational Medicine, 2015, v. 4, n. 3, p. 252, doi. 10.5966/sctm.2014-0133
- By:
- Publication type:
- Article
Lessons Learned From Fatal Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Sclerosis Treated With Natalizumab.
- Published in:
- JAMA Neurology, 2013, v. 70, n. 3, p. 398, doi. 10.1001/jamaneurol.2013.1960
- By:
- Publication type:
- Article
The Potential Role of B Cell-Targeted Therapies in Multiple Sclerosis.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
Disease-Modifying Agents for Multiple Sclerosis: Recent Advances and Future Prospects.
- Published in:
- Drugs, 2008, v. 68, n. 17, p. 2445, doi. 10.2165/0003495-200868170-00004
- By:
- Publication type:
- Article
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
- Published in:
- Drug Design, Development & Therapy, 2014, v. 8, p. 897, doi. 10.2147/DDDT.S50962
- By:
- Publication type:
- Article
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. 4, p. 158, doi. 10.7224/1537-2073.2018-087
- By:
- Publication type:
- Article
(QOL01) Alemtuzumab Effects on Urogenital Function: Results Pooled From the CARE-MS 9-Year Functional Assessment of Multiple Sclerosis Quality-of-Life Survey.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 63
- By:
- Publication type:
- Article
(DMT02) Yearly Efficacy and Safety Outcomes Over 4 Years After Last Alemtuzumab Course in Pooled CAREMS I and II Patients by Number of Additional Courses Received Through Year 9.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 4
- By:
- Publication type:
- Article
Poster 67 Best Practices in Intrathecal Baclofen Therapy: Dosing and Long‐Term Management.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2015, v. 7, p. S113, doi. 10.1016/j.pmrj.2015.06.108
- By:
- Publication type:
- Article
Poster 67 Best Practices in Intrathecal Baclofen Therapy: Dosing and Long-Term Management.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2015, v. 7, p. S113, doi. 10.1016/j.pmrj.2015.06.108
- By:
- Publication type:
- Article
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/1756286420982134
- By:
- Publication type:
- Article
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/1756286420982134
- By:
- Publication type:
- Article
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2011, v. 4, n. 5, p. 319, doi. 10.1177/1756285611422108
- By:
- Publication type:
- Article
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database.
- Published in:
- Neurology & Therapy, 2017, v. 6, n. 1, p. 91, doi. 10.1007/s40120-017-0064-x
- By:
- Publication type:
- Article